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Abstract
Background: A system that can deliver multi-drug at a prolonged rate is very important for the treatment of
various chronic diseases such as diabetes, asthma and heart disease. Controlled porosity osmotic pump tablet
(CPOP) system was designed to deliver Nifedipine (NP) and Metoprolol (MP) in a controlled manner up to 12 h. It
was prepared by incorporating drugs in the core and coated with various types (PVP, PEG-400 and HPMC) and
levels (30, 40 and 50% w/w of polymer) of pore former at a weight gain of 8, 12 & 15%.
Results: Formulation variables like type and level of pore former and percent weight gain of membrane was found
to affect the drug release from the developed formulations. Drug release was inversely proportional to the
membrane weight but directly related to the level of pore former. Burst strength of the exhausted shell was
inversely proportional to the level of pore former, but directly affected by the membrane weight. Results of
scanning electron microscopy (SEM) studies showed the formation of pores in the membrane from where the
drug release occurred. Dissolution models were applied to drug release data in order to establish the mechanism
of drug release kinetics. In vitro release kinetics was subjected to superposition method to predict in vivo
performance of the developed formulation.
Conclusion: The developed osmotic system is effective in the multi-drug therapy of hypertension by delivering
both drugs in a controlled manner.
Keywords: Controlled porosity osmotic pump tablet CPOP, Controlled osmotic drug delivery, Nifedipine, Metopro-
lol, Osmotic pump
Background
Approximately one quarter of the total global popula-
tion is affected by at least any one of the cardiovascular
disease (CVD) [1]. It caused 2.3 million deaths in India
i n1 9 9 0 ,w h i c hm a yd o u b l eb yy e a r2 0 2 0 ,w h e r eh y p e r -
tension alone contribute 57% of all stroke death and
24% of all coronary heart disease [2]. Hypertension is a
common cause of cardiovascular disorders and is essen-
tially associated with abnormal lipid and altered glucose
metabolism [3,4]. Several studies revealed that a reduc-
tion in blood pressure reduces the risk and incidence of
CVD [5,6]. Thus management of cardiovascular disease
in particular the hypertension becomes important to
improve health care system. Several multidrug therapies
are prescribed for successful management of CVD, in
which chronic diseases such as hypertension, diabetes,
asthma etc., are treated using multidrug therapies,
which are vulnerable to incidences of side-effects, poor
patient compliance and slow improvement of patients.
Nifedipine (NP) and Metoprolol tartarate (MP) are anti-
hypertensive agents belonging to calcium channel block-
ers and b-blockers respectively. Generally, they are
either used individually or as combination therapy to
treat hypertension. Though NP and MP is administered
as immediate release solid oral dosage form, a short
elimination half life with significant fluctuation in
plasma concentration necessitate it to be formulated
into modified release dosage forms. Recently, it was
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release dosage forms decreased morbidity and mortality,
prevents myocardial infarction in diabetes mellitus
patients and reduces atherosclerosis in carotid and cor-
onary arteries [7]. These facts justify our interest in con-
trolled release dosage form. We have recently developed
controlled release formulation of NP and MP based on
sandwiched osmotic delivery system [8]. Osmotic drug
delivery was attempted since, though a number of design
options are available to control the drug release from a
dosage form, majority of the oral dosage form fall in the
category of matrix, reservoir or osmotic systems. Drug
release from osmotic system is independent of pH and
gastrointestinal motility to a large extent [9]. The devel-
opment of oral osmotic systems has a strong market
potential, as evident from the marketed products and
number of patents granted in the last few years [10].
From a technical standpoint, the controlled delivery of
NP is difficult since it is practically insoluble in water
and aqueous fluids due to its high crystalline nature and
exhibits poor dissolution rate. Various attempts were
made to improve the dissolution rate of NP which
include solid dispersion in water soluble carriers such as
urea [11], PVP (Polyvinyl pyrrolidone) [12], PVP-MCC
and HIPC-MCC [13] complexation with cyclodextrin.
Skalko et al., [14] reported the feasibility of using NP-
cyclodextrin complex as a core for microcapsule in
order to obtain controlled release. Besides, recently
Ramesh and Chowdary, [15] reported sustained release
two layered tablet formulations of NP using NP-hydro-
xyproyl-b-cyclodextrin (1:1) inclusion complex. In the
present investigation,1 : 1N P - h y d r o x y p r o y l - b-cyclodex-
trin (NHb-CD) complex was used to improve NP disso-
lution rate and solubility.
There was a report of simultaneous delivery of drugs
having extremely different solubility profile through ele-
mentary osmotic pump using highly water soluble drug
as both osmotic agent and active ingredient to deliver it
along with water insoluble drug [16]. Based on this
report attempt was made to simultaneously deliver NP
(water insoluble drug) and MP (highly water soluble
drug) using the same approach. Instead, we tried con-
trolled porosity osmotic pump (CPOP) system since pre-
paration of CPOP is simple; it is not necessary to
consider complicated side drilling and compared to
other osmotic pump systems less excipients is required.
The coating composition of CPOP includes pore-form-
ing agent, which generates pores in contact with aqu-
e o u sm e d i a[ 1 7 ] .I tw a so b s e r v e dt h a tm o s to ft h ec o r e
content releases through pores at a constant rate, where
the release mechanism primarily is osmotic with simple
diffusion playing a minor role. A zero-order delivery
pattern was designed to produce plasma levels within
the desired range. Different formulation variables were
studied and optimized to achieve the desired release
profile. Besides, the in vivo performance of the opti-
mized formulation was predicted.
Materials and methods
Materials
Nifedipine (micronized) and Metoprolol tartarate were a
kind gift sample from Madras Pharmaceuticals Private
Limited, Chennai, India. Hydroxy propyl b-cyclodextrin
(Hb-CD) was purchased from Sigma-Aldrich, Bangalore.
PVP (K-30) was purchased from s.d. Fine Chemicals
Ltd, India. Hydroxy propyl methylcellulose (HPMC),
Polyethylene glycol-400 (PEG-400) was obtained from
Loba Chemie, Mumbai, India. Micro crystalline cellulose
(MCC), magnesium stearate and aerosil were purchased
from Rolex, Mumbai, India. Cellulose acetate (CA) was
obtained from Eastman Chemical Company, Kingsport,
U.S.A. All other solvents and chemicals used were of
the analytical grade.
Methods
Preparation of Nifedipine b-cyclodextrin inclusion complex
Solid complex of NHb-CD were prepared in 1:1 ratio by
co-precipitation method. NP was first dissolved in a
small volume of acetone and then thoroughly mixed
with 100 ml of ethanolic solution of carrier in a round
bottom flask. The solvent was evaporated under reduced
pressure at 40°C (Rotary evaporator RE120, Buchi, Swit-
zerland) and stored in dessicator.
Preparation of tablets
Core tablets were prepared by wet granulation and the
composition is given in table 1. For preparation of core
tablets, the batch size was kept as 100 tablets. NHb-CD
and MP was mixed with starch and dicalcium phosphate
and the blend was further mixed for 10 min. The mix-
ture was moistened with PVP solution in isopropyl alco-
hol and granulated by passing through 12 sieve. The
granules were dried at 50°C (approximately 1 h) after
which they were passed through 18 sieve. These sized
granules were then blended with magnesium stearate,
talc and aerosil (all 120 sieve passed) and compressed
Table 1 Composition of core tablets of CPOP
Ingredients Amount (mg)
NHb-CD Complex 75
Metoprolol tartarate 55
Starch 10
Dicalcium phosphate 15
PVP 15
Isopropyl alcohol Q.S
Aerosil 10
Talc 10
Magnesium stearate 02
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(Cadmac, India) fitted with 12/32 inch deep concave
punches. The core tablets were coated in an automated
perforated pan (Cipweka, India). The composition
of coating solution used for coating tablets is given in
table 2. Various components of the coating solution
were added to the solvent mixture in a sequential man-
ner. The component added first was allowed to dissolve
before the next component was added. Initially, pan was
rotated at low speed (2-5 rev/min) and heated air was
passed through the tablet bed. Coating process was
started once the outlet air temperature reached 28°C.
Coating pan rpm was kept in the range of 12-15 and
coating solution was sprayed at the rate of 3-5 ml/min.
Coating was continued until desired weight gain was
obtained on the active tablets. In all the cases, active
tablets were dried at 50°C for 2 h before further
evaluation.
Evaluation of the developed formulations
The developed formulations were subjected to release
studies using USP-II dissolution apparatus (Electrolab,
India) at 100 rpm. Dissolution medium used was phos-
phate buffer (pH 6.8, 900 ml) containing sodium lauryl
sulphate 0.5% maintained at 37 ± 0.5°C. The samples
w e r ew i t h d r a w n( 1 0m l )a t0 ,2 ,4 ,6 ,8 ,1 0a n d1 2h
intervals and replaced with an equivalent amount of
fresh medium. The dissolution sample after filtration
through 0.45 μm cellulose acetate filter were analyzed
using a validated UV spectrophotometric method at 340
nm for NP and 275 nm for MP. Each study was done in
triplicate and the mean values were reported. After ana-
lyzing the drug content in the dissolution samples, the
graph of cumulative percentage of drug release versus
time was plotted. All experiments were carried out
under strict protection from light to prevent undesirable
photo-degradation of NP throughout the entire experi-
mental procedure.
Mathematical comparisons of dissolution curves from
various formulations provide an opportunity to test the
similarity between two dissolution profiles. Fit factors (f1
and f2) proposed by Moore and Flanner, [18] were used
for comparing the dissolution profile of pH and
agitation studies. An f2 value of ≥50 indicates similarity
between two dissolution curves, whereas f1 is used as an
additional parameter to confirm the similarity when the
value is ≤15. For the calculation of f1 and f2 values, only
one data point was taken into consideration after 85% of
the drug was released.
Formulation variables
In order to optimize the formulation to release the drug
at a constant zero-order release rate, level of pore for-
mer, type of pore former and coating thickness were
used as formulation variables [19]. The respective for-
mulation code and variables were given in table 2
Effect of type and level of pore former
To study the effect of pore former on the drug release,
PVP, PEG-400 and HPMC were used as pore former at
the level of 0, 30, 40 and 50% (w/w) of CA.
Effect of coating thickness on drug release
The tablets coated to three level of weight gain, such as
8, 12 and 15% (w/w) in order to assess the effect of
coating thickness on drug release.
Burst strength
Burst strength of the exhausted shells, after dissolution
was determined to assure that the tablets would main-
tain their integrity in the gastrointestinal tract (GIT).
Burst strength was determined as the force required to
break/rupture the shells after dissolution studies. The
texture analyzer (Instron 4501, India) with a 5 kg load
cell and 25 mm aluminum cylindrical probe was utilized
for this purpose. Test speed of 0.8 mm/s with a distance
of 2 mm was selected.
Scanning electron microscopy studies
In order to elucidate the mechanism of drug release
from the developed formulations, surface of coated
tablets before and after dissolution studies, was studied
using scanning electron microscope (SEM). The samples
were placed on a spherical brass stub (12 mm diameter)
with a double backed adhesive tape. Small sample of the
coating membrane was carefully cut from the exhausted
shells (after dissolution studies) and dried at 50°C for 2
h. The mounted samples were sputter coated for 2 min
with gold using fine coat ion sputter (JFC-1600, Jeol,
Japan) with pressure of 8 kg Pascal and examined under
SEM (JSM-6360, Jeol, Japan).
Effect of pH
In order to study the effect of pH and to assure a reli-
able performance of the developed formulations inde-
pendent of pH, release studies of the optimized
formulations were conducted in media of different pH,
simulated gastric fluid (SGF) pH 1.2, simulated intestinal
fluid (SIF) pH 6.8 and pH change method (release media
was SGF for first 2 h, followed by SIF for the remaining
period). The sample (10 ml) was withdrawn at pre-
determined intervals and analyzed after filtration
through 0.45-μm cellulose acetate filter. The percentage
Table 2 Formulation variables of controlled porosity
osmotic pump tablet
Coating
components
Formulation code
CF1 CF2 CF3 CF4 CF5 CF6 CF7 CFW
CA (% w/v) 4 4 4 4 4 4 4 4
PVP (% w/w of CA) 30 40 50 - - - 0
PEG 400 (% w/w of CA) - - - 40 40 40 -
HPMC (% w/w of CA) - - - - 40 - - -
Thickness (%) 8 8 8 8 8 12 15 8
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various pH was plotted and compared.
Effect of agitational intensity
In order to study the effect of agitational intensity of the
release media, release studies of the optimized formula-
tions were carried out in dissolution apparatus at var-
ious rotational speeds. Dissolution apparatus used was
USP-II at 50, 100 and 150 rpm. Sample was withdrawn
at pre-determined intervals and analyzed after filtration
through 0.45 μm cellulose acetate filter. The percentage
cumulative drug release of optimized formulations at
different agitational intensity was plotted and compared.
Osmotic pressure measurement
In order to confirm the mechanism of drug release,
release studies of the optimized formulations were con-
ducted in media of different osmotic pressure. To
increase the osmotic pressure of the release media,
sodium chloride (Osmotically effective solute) was
added in SIF [20] and osmotic pressure was measured
(Fiske micro osmometer, 210). The pH was adjusted to
6.8 ± 0.05. Release studies were carried out in 900 ml of
media using USP II dissolution test apparatus (100
rpm). Release profiles of the optimized formulations at
different osmotic pressure was plotted and compared.
Curve fitting analysis
In order to describe the kinetics of drug release from
controlled release preparations various mathematical
equations have been proposed. Release data obtained
was applied to different release models in order to
establish the drug release mechanism and kinetics. Best
goodness of fit test (R
2) was taken as criteria for select-
ing the most appropriate model [21].
In vivo performance prediction of selected formulation
Drug-release parameters (R
0 and tdel) obtained from in
vitro data and the pharmacokinetic properties of drugs
were used for predicting blood drug concentration-
t i m ep r o f i l ef r o ms i n g l ed o s ea n da ts t e a d ys t a t ef r o m
multiple dosing. The method of superposition was
used for the steady-state concentration predictions
[22]. It was assumed that after the administration of a
test dose of formulation, the drug would be released at
a release rate (R
0) for a period of time (tdel)s h o r t e r
than the selected dosing interval (τ). Values of Cssmax
and Cssmin, maximum and minimum steady-state con-
centration, respectively, were compared with the
desired values calculated from a theoretically devel-
oped controlled drug-release profile [23]. The pre-
dicted steady-state plasma level of developed
formulation was compared with the desired levels by
calculating the percent predicted error (% PD) in
CSSmax,C ssmin and AUC0-τ. Bioequivalence was antici-
pated [24] if the average % PD was less than 15%. The
% PD was calculated using the following equation:
% PD =
Predicted value − reference value
Reference value
× 100
Result and Discussion
Desired drug release profile
The purpose of this study was to develop a delivery sys-
tem for short half life drugs NP and MP which can deli-
ver these drugs in a controlled manner for 12 h. The
dose, the delivery time and the dosing interval are the
key features for any temporal controlled release system.
The desired steady-state concentration for NP to the
therapeutically acceptable range is 15-75 ng/ml [25]. In
the present study, steady state concentration was
selected as 15-60 ng/ml. Similarly, MP steady state
plasma concentration was reported as 25-46 ng/ml [26].
The same plasma concentration was selected in this
study. Taking different pharmacokinetic parameters of
NP and MP into consideration, a zero-order based deliv-
ery strategy was designed to produce the desired plasma
levels [22]. Series of simulations (using Microsoft Excel
2003) were performed and it was found that a delivery
rate of 1.68 mg/h for a period of 5.19 h and 4.2 mg/h
for a period of 8.8 h was found to meet the above
requirements for NP and MP respectively.
Formulation development
The compatibility of NP, MP with the excipients used for
formulation development was tested using differential
scanning calorimetry (DSC). The changes in the
endotherm observed in case of CPOP tablet (melting
endotherm of NHb-CD at 154.6°C and MP at 131.2
°C,
Figure 1) for the original melting endotherm (figure not
shown) of NHb-CD (169.7
°C) and MP (146.27
°C) was
minor. Hence it was clear that no specific interaction
between the drug and excipients used in the present for-
mulation. In general, both highly and poorly water-solu-
ble drugs are not good candidates for osmotic delivery.
As previous study demonstrated increased solubility of
NP by complexation with Hb-CD, we also prepared
inclusion complex of NHb-CD (1:1) by co-precipitation
method. Solubility of NP in distilled water at 25°C was
6.24 μg/ml whereas the solubility of prepared complex
was found to be 15 μg/ml. Phase solubility studies of
NHb-CD systems in water at 25°C revealed that the solu-
bility of NP increased linearly with the increase in the
concentration of Hb-CD, showing a typical AL-type
phase solubility curve. This curve may be ascribed to the
formation of a stoichiometric 1:1 complex of NP and Hb-
CD. The apparent 1:1 stability constant (KC) was calcu-
lated from the straight line of the phase solubility dia-
gram and constant value was found to be 10.35 M
-1.
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NHb-CD and MP along with other excipients. Tablet
core consists of drugs and other conventional excipients
to form the core compartment. The core compartment is
surrounded by a membrane consisting of a semiperme-
able membrane-forming polymer, water-soluble pore-
forming additives and at least one plasticizer capable of
improving film forming properties of the polymers. The
semipermeable membrane-forming polymer is permeable
t oa q u e o u sf l u i d sb u ts u b s t a n t i a l l yi m p e r m e a b l et ot h e
components of the core. In operation, the core compart-
ment imbibes aqueous fluids from the surrounding envir-
onment across the membrane and dissolves the drug.
The dissolved drugs are released through the pores cre-
ated after leaching of water-soluble additive(s) in the
membrane. CA was used as water insoluble polymer.
PVP, PEG-400 and HPMC were tried as pore formers.
Diethyl phthalate (DEP) 20% was used as a plasticizer.
We attempted to deliver NP and MP by adding highly
water soluble MP in to the NHb-CD tablets as both
active agent and also as an osmotic agent. The release of
NP was enhanced owing to osmotic effect of MP and
further MP was also delivered simultaneously.
Influence of tablet formulation variables on NP and MP
release
To study the influence of tablet formulation variables on
drug release, tablets with various formulations were pre-
pared, subsequently coated with the coating thickness of
8% and plasticized with 20% DEP.
Effect of level of pore former
To study the effect of level of pore former (PVP), core
tablets were coated with coating composition containing
0, 30, 40 and 50% (w/w) of PVP (formulations: CFW,
CF1, CF2 and CF3 respectively). It was found that the
drug release increased with increase in the level of pore
former (Figure 2). As the level of pore former increases,
the membrane becomes more porous after coming in
contact with the aqueous environment, resulting in fas-
ter drug release. Other workers have also obtained simi-
lar results [27,28]. At levels up to 30% and 40% (w/w) of
pore former, numbers of pores were sufficient to contri-
bute to significant drug release. On the other hand,
membrane that contained 50% (w/w) of pore former;
the release profile was faster since it became highly por-
ous after coming in contact with water. Another para-
meter affected by the level of pore former was burst
strength of the exhausted shells. The burst strength was
inversely related to the initial level of pore former in the
membrane. With the increase in level of PVP, the mem-
brane became more porous after exposure to water,
leading to decrease in its strength. Effect of level of PVP
on burst strength is shown in table 3. Since, satisfactory
drug release and adequate burst strength were obtained
in case of formulations with 40% pore former level
(CF2); this concentration was selected for further
studies.
Effect of type of pore former
To study the effect of type of pore former, formulations
CF2, CF4 and CF5 were prepared by coating core tablets
of NP and MP with coating compositions containing
different pore formers PVP 40% (CF2), PEG-400 40%
(CF4) and HPMC 40% (CF5). As evident from Figure 3,
the type of pore former affected drug release and it is
possible to achieve the desired release by using different
types of pore formers. It has been reported that water-
Figure 1 DSC thermogram of NHb-CD and meoprolol combination CPOP.
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leach out of the coating, forming a porous film with
increased permeability [29] or produce hydrated water
filled HPMC regions within the membrane that allow
drug transport across the film. The percentage drug
release was more in case of PEG-400 as pore former,
since it is more hydrophilic plasticizer than PVP and
HPMC, it could be leached out easily and increases the
flux rate of fluid. The poor drug release pattern of
HPMC may result from the increased tortuosity or gel
strength of the polymer. In addition to release, type of
pore former also affected the burst strength of the
exhausted shells (table 3) and this parameter should also
be taken into consideration while selecting the pore for-
mer. The drug release pattern and the burst strength
were satisfactory with the formulations containing PEG-
400 (CF4) as the pore former. This formulation was
selected as the optimized formulation and used for
further evaluation.
Effect of weight gain
To study the effect of weight gain of the membrane,
coating on the core tablets of NP was continued for suf-
ficient duration so as to get tablets with different weight
gain 8 (CF4), 12 (CF6) and 15% (CF7). Release profile of
NP and MP as a function of weight gain of the mem-
brane is shown in Figure 4. Drug release was found to
decrease with an increase in the weight gain of the
membrane. The burst strength of these formulations
were also observed (Figure 5). Though CF4 and CF6
showed higher drug release pattern, comparatively an
approximate zero order release pattern and better burst
strength was observed with CF6. In case of 15% (CF7)
thickness slow release pattern was observed. This is due
to the increased polymer loading. The more the weight
gain, the more would be the lag time. No bursting of
the systems was observed during the dissolution run in
any of the formulations. In addition, exhausted tablets
(after 12 h of dissolution studies) were evaluated for
burst strength to assure that the tablets maintain their
integrity in GIT and do not lead to dose dumping.
The strength of mechanical destructive forces in the
G I To fh u m a n sa n dd o g sh a sb e e nr e p o r t e dt ob e1 . 9
N (approximately 190 g) and 3.2 N (approximately
320 g), respectively [30,31]. In a previous study, it has
been reported that osmotic pumps having the burst
strength in the range of 500-600 g were intact in the
GIT of dogs while those having burst strength of
around 200 g were compromised [32]. In all cases of
our investigation the value of burst strength is much
0
10
20
30
40
50
60
70
80
90
100
02468 1 0 1 2
Time (h)
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
 NP-CF1 30% PVP NP-CF2 40% PVP NP-CF3  50% PVP
MP CF1 30%PVP MP-CF2 40% PVP MP-CF3  50% PVP
Figure 2 Effect of level of pore former on release of NP and MP.
Table 3 Effect of level and type of pore former on burst
strength
S.No Pore former (% w/w of CA) Burst strength (MPa)
1 PVP (0) 50
2 PVP (30) 14.25
3 PVP (40) 8.18
4 PVP (50) 5.31
5 PEG-400 (40) 18.25
6 HPMC (40) 8.37
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Page 6 of 13higher than the mechanical destructive forces in GIT,
thus assuring that the formulations can be expected to
remain intact in GIT without any incidence of dose
dumping. It was found that an approximate zero-
order release rate pattern up to 12 h and sufficient
burst strength was obtained in the case of the 12%
coating thickness. Hence CF6, PVP-40% and weight
gain of 12% was used as optimized formulation for
further evaluations.
Kinetics and Mechanism of drug release
Drug-release data from the optimized formulation was
fitted to various kinetic models to elucidate the mechan-
ism and kinetics of drug release (table 4). Best goodness
of fit test (R
2) was taken as criteria for selecting the
most appropriate model. The data fit well into the zero
o r d e rk i n e t i c s .T h ec o m p a t i b l ef i to ft h ez e r oo r d e r
kinetics indicated that the drug release is controlled by
a concentration independent release mechanism.
0
10
20
30
40
50
60
70
80
90
100
1234567
Time (h)
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
 NP-CF2 40%  PVP  NP-CF4 40%  PEG NP-CF5 40%  HPMC
MP-CF2  40%  PVP MP-CF4  40%  PEG MP-CF5  40%  HPMC
Figure 3 Effect of type of pore former on release of NP and MP.
0
10
20
30
40
50
60
70
80
90
100
02468 1 0 1 2
Time (h)
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
NP-CF4 8% NP-CF6 12% NP-CF7 15% MP-CF4 8% MP-CF6 12% MP-CF7 15%
Figure 4 Effect of weight gain on release of NP and MP.
Kumaravelrajan et al. Lipids in Health and Disease 2011, 10:51
http://www.lipidworld.com/content/10/1/51
Page 7 of 13To investigate the changes in the membrane structure,
surface of coated tablets was studied using SEM.
Figure 6, 7 &8 showed SEM micrographs of membrane
surface of developed formulations CF2, CF4 and CF5
containing 40% of PVP, PEG-400 and HPMC before and
after dissolution studies. After dissolution studies, coat-
ing was intact without any cracks. However, there was
formation of channels/pores in the membrane, which
possibly acted as exit ports for the drug.
Figure 6a, 7a and 8a showed the membrane structure
before dissolution studies. In all the cases, no significant
difference was observed between different types of pore
former (PVP, PEG-400 and HPMC). The surface of
coated tablet was smooth before coming into contact
with the aqueous environment and the coats appeared
to be free of point defects.
When comparison was made among the membrane
containing different types of pore formers after dissolu-
tion studies, it was found that the membrane that con-
tained PVP (Figure 6b), PEG-400 (Figure 7b) and
HPMC (Figure 8b) developed pores. But the size and
number of pores are more in case of PEG-400. The
membrane becomes more porous, because of leaching
of pore former from the membrane.
Effect of pH
In order to study the effect of pH on drug release,
release studies were conducted in media of different pH.
To study the effect of pH and to assure a reliable in-
vivo performance, release study of the optimized formu-
lation was conducted according to pH change method
and compared with release profile in SIF (pH 6.8). Table
5 showed release of NP and MP from optimized formu-
lation of CPOP (CF6) in pH 1.2; pH change method and
pH 6.8 respectively. The f1 and f2 values were found to
be 3 and 78 (between pH 1.2 and pH 6.8), 3 and 76
(between pH change method and pH 6.8) for NP and 2
and 81 (between pH 1.2 and pH 6.8), 3 and 77 (between
pH change method and pH 6.8) for MP respectively. As
can be seen from table 5, release profile is similar in all
the media demonstrating that the developed formula-
tions show pH-independent release.
Effect of agitational intensity
Drug release from osmotic pumps to a large extent is
independent of agitation intensity of the release media.
To study the effect of agitational intensity of the release
media, release studies of the optimized formulation of
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Figure 5 Burst strength of the membrane as function of weight gain.
Table 4 Fitting of NP and MP release data of the
optimized formulation (CF6) according to various
mathematical models
Model Parameters used to assess the fit of model
R
2 Intercept K AIC
NP MP NP MP NP MP NP MP
Zero
order
0.9986 0.9994 0.239 0.741 1.48 3.94 5.08 -0.99
First
order
-0.9174 -0.9134 2.09 2.09 -0.16 -0.17 -30.32 -29.39
Higuchi 0.9649 0.9671 -11.68 -11.35 25.6 25.84 33.92 33.72
R
2 -Goodness of fit.
K - Release rate constant for respective models (K0 in mg/hr, K1 in h
-1 and KH
in % h
1/2 for zero order, first order and Higuchi rate equations respectively).
AIC - Akaike information criterion
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Page 8 of 13CPOP (CF6) were carried out in USP dissolution appa-
ratus type II at varying rotational speed (50, 100 and
150 rpm). It is clearly evident from table 6 that the
release of NP and MP from CPOP is independent of the
agitational intensity. The f1 and f2 values were found to
be 5 and 69 (between pH 1.2 and pH 6.8), 4 and 69
(between pH change method and pH 6.8) for NP and 4
and 67 (between pH 1.2 and pH 6.8), 3 and 77 (between
pH change method and pH 6.8) for MP respectively.
Hence, it can be expected that the release from the
developed formulation will be independent of the hydro-
dynamic conditions of the absorption site.
Effect of osmotic pressure
The effect of osmotic pressure on the optimized formu-
lation was studied in media of different osmotic pres-
sure, and the release profile with varying osmotic
pressure is depicted in table 7. The results of release
studies of optimized formulations in media of different
osmotic pressure indicated that, the drug release is
highly dependent on the osmotic pressure of the release
media. NP and MP release from the formulations
decreased as the osmotic pressure of the media
increased. The release was inversely related to the osmo-
tic pressure of the release media. This finding confirms
that the mechanism of drug release is by the osmotic
pressure.
Prediction of in vivo concentration-time profile from in
vitro data
Method of superposition was used to predict steady
state plasma levels of NP and MP after administration
of CF6 formulation [22]. A steady state drug concentra-
tion-time profile for the optimized tablet was predicted
using its in vitro zero order kinetic release rate. Because
the release rate of drugs from the tablets was slightly
lower than the desired level, the predicted drug concen-
trations were also proportionately lower to the desired
(a )                                                      ( b)
Figure 6 SEM micrograph of 40% PVP (a) before and (b) after dissolution studies.
(a)                                                               (b)
Figure 7 SEM micrograph of 40% PEG-400 before (a) and after (b) dissolution studies.
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Figure 8 SEM micrograph of 40% HPMC before (a) and after (b) dissolution studies.
Table 5 Effect of pH on release of NP and MP from CF6 (n = 3)
Time
(h)
Cumulative % release ± SEM
NP MP
pH 6.8 pH 1.2 pH change pH 6.8 pH 1.2 pH change
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2 13.28 ± 0.68 12.60 ± 1.30 13.40 ± 0.71 15.31 ± 1.71 12.52 ± 2.31 12.02 ± 1.35
4 31.81 ± 1.23 29.50 ± 1.89 27.40 ± 1.12 31.71 ± 1.20 28.50 ± 2.44 26.50 ± 2.50
6 44.74 ± 1.50 41.31 ± 2.80 39.08 ± 1.54 45.66 ± 3.12 42.12 ± 2.09 40.82 ± 1.51
8 59.28 ± 1.91 55.90 ± 2.30 53.62 ± 2.31 59.41 ± 2.96 56.95 ± 2.61 53.40 ± 2.97
10 73.15 ± 0.21 70.12 ± 2.67 67.93 ± 3.02 75.27 ± 2.31 72.85 ± 3.42 70.16 ± 2.46
12 88.14 ± 1.10 85.41 ± 1.80 85.20 ± 2.86 89.13 ± 1.90 87.09 ± 3.79 86.40 ± 1.83
Table 6 Effect of agitational intensity on release of NP and MP from CF6 (n = 3)
Cumulative % of release ± SEM
NP MP
Time
(h)
100 RPM 50 RPM 150 RPM 100 RPM 50 RPM 150 RPM
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2 8.50 ± 0.71 13.28 ± 0.68 14.50 ± 1.30 11.41 ± 2.31 15.31 ± 1.71 18.21 ± 1.35
4 27.35 ± 1.12 31.81 ± 1.23 34.21 ± 1.89 27.80 ± 2.44 31.71 ± 1.20 33.4 ± 2.5
6 38.46 ± 1.54 44.74 ± 1.50 47.41 ± 2.80 41.04 ± 2.09 45.66 ± 3.12 49.50 ± 1.51
8 55.92 ± 2.31 59.28 ± 1.91 62.53 ± 2.30 55.71 ± 2.61 59.41 ± 2.96 63.21 ± 2.97
10 65.13 ± 3.02 73.15 ± 0.21 77.08 ± 2.67 71.58 ± 3.42 75.27 ± 2.31 77.81 ± 2.46
12 83.53 ± 2.86 88.14 ± 1.10 91.73 ± 1.80 85.02 ± 3.79 89.13 ± 1.90 93.41 ± 1.83
Table 7 Effect of osmotic pressure on release of NP and MP from CF6
Time
(h)
Cumulative % of drug release
NP MP
CF6 7.8 atm 13.85 atm 21.27 atm CF6 7.8 atm 13.85 atm 21.27 atm
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 13.28 8.50 5.20 3.10 15.31 10.20 6.21 3.45
4 31.81 24.30 18.40 12.30 31.71 24.60 18.20 12.00
6 44.74 33.20 30.10 22.40 45.66 38.60 29.50 21.40
8 59.28 48.40 41.50 29.50 59.41 50.00 39.50 30.20
10 73.15 65.00 56.40 45.30 75.27 66.14 58.70 50.36
12 88.14 79.10 68.00 58.60 89.13 79.50 70.13 64.20
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Page 10 of 13concentrations. Prediction of steady-state levels of NP
and MP after administration of a test dose of formula-
tion showed that peak plasma levels were 58 (NP) and
45.98 ng/ml (MP) but falls to14.8 (NP) and 25 ng/ml
(MP) at steady state (Figure 9, 10). The predicted
CSSmax,C SSmin and AUC0- τ after administration of for-
mulation of NP and MP, in comparison with the desired
ones are listed in table 8. The % PD of the steady-state
parameters of CF6 formulation was calculated taking the
data of desired profile as the reference. The absolute %
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Figure 9 Predicted steady-state concentration of NP in comparison with the desired profile.
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Figure 10 Predicted steady-state concentration of MP in comparison with the desired profile.
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Page 11 of 13PD was found to be less than 15%, ensuring that the
formulation will produce plasma levels close to the
d e s i r e do n e s .T h u s ,i tc a nb ec o n c l u d e dt h a tt h ed e v e l -
oped formulation (CF6) will produce plasma levels well
within the therapeutic range and similar to those pro-
duced by the desired zero order delivery profile.
Conclusion
In the present study an oral osmotic system was devel-
oped that can deliver NP and MP simultaneously. This
study suggests that drug release from these systems is
controlled by osmotic pressure as the major mechanism;
release pattern followed zero order kinetics and inde-
pendent of environmental medium and the mobility of
the gastrointestinal tract. The feasibility of extending the
zero order release pattern of both the drugs were better
achieved with controlled porosity osmotic pump tablet
system between 10-12 h. The prototype design of the
system could be applied to other combinations of drugs
(one slightly water soluble or insoluble drug and another
freely water soluble drug) used in cardiovascular dis-
eases, diabetes etc.
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